Lexeo Therapeutics, Inc.
LXEO
$4.61
-$0.12-2.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.08% | 123.70% | 35.82% | 47.38% | -4.23% |
| Gross Profit | -9.08% | -123.70% | -35.82% | -47.38% | 4.23% |
| SG&A Expenses | 120.35% | 33.29% | 168.25% | 155.20% | 164.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.14% | 82.86% | 55.59% | 68.52% | 20.74% |
| Operating Income | -45.14% | -82.86% | -55.59% | -68.52% | -20.74% |
| Income Before Tax | -50.61% | -82.73% | -46.65% | -58.01% | -16.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.61% | -82.73% | -46.65% | -58.01% | -16.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.61% | -82.73% | -46.65% | -58.01% | -16.21% |
| EBIT | -45.14% | -82.86% | -55.59% | -68.52% | -20.74% |
| EBITDA | -45.50% | -83.74% | -56.00% | -69.06% | -20.73% |
| EPS Basic | -27.27% | 9.18% | 92.78% | 92.25% | 93.31% |
| Normalized Basic EPS | -27.21% | 9.10% | 92.79% | 92.25% | 93.31% |
| EPS Diluted | -27.27% | 9.18% | 92.78% | 92.25% | 93.31% |
| Normalized Diluted EPS | -27.21% | 9.10% | 92.79% | 92.25% | 93.31% |
| Average Basic Shares Outstanding | 18.35% | 101.21% | 1,932.53% | 1,937.78% | 1,637.01% |
| Average Diluted Shares Outstanding | 18.35% | 101.21% | 1,932.53% | 1,937.78% | 1,637.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |